GlassScriptPhysician profile
Daniel W Sherbenou
NPI 1104053438
$18,082.06
in general payments reported to CMS, 2019-2025
14 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.44 · 2021: $1,300 · 2022: $588 · 2023: $1,585 · 2024: $13K · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $1,278 · Travel and Lodging: $730 · Education: $3.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,139.50 |
| Food and Beverage | $1,277.81 |
| Travel and Lodging | $729.74 |
| Education | $3.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11,728.13 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $3,262.21 | 2022-2025 | Tecvayli, Talvey, Carvykti |
| Glaxosmithkline, LLC. | $1,330.63 | 2021-2024 | Blenrep |
| Janssen Biotech, INC. | $1,329.87 | 2023-2025 | Tecvayli |
| Karyopharm Therapeutics INC. | $266.49 | 2022-2023 | Xpovio |
| Abbvie INC. | $71.28 | 2025 | |
| Secura Bio, INC. | $43.44 | 2019 | |
| Amgen INC. | $21.76 | 2023 | Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.77 | 2022 | |
| Pfizer INC. | $11.48 | 2022-2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sherbenou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.